Migalastat vs pegunigalsidase alfa

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Fabry Disease

Shared mechanism: Alpha-galactosidase A (GLA / α-Gal A) · full Fabry Disease pipeline

Migalastat · Galafold

Marketed by Amicus Therapeutics and partners

Approved in Fabry Diseasesmall molecule
Partial signal

NCT00925301 · Phase 3 · completed

Participants were randomized and double-blinded to migalastat or placebo, with 34 and 33 participants assigned respectively. The primary endpoint was a kidney biopsy measure of GL-3 inclusions, a surrogate pathology measure rather than a direct clinical outcome; 13 of 32 migalastat-treated participants versus 9 of 32 placebo-treated participants achieved the target reduction, but the comparison was not statistically significant (p=0.2996).

Next expected readout: December 2026 · NCT04020055 (registry estimate)

Reported efficacy

Percentage Of Participants With At Least A 50% Reduction From Baseline To Month 6 In The Average Number Of Kidney Interstitial Capillary (IC) Globotriaosylceramide (GL-3) Inclusions (Baseline, Month 6): Percentage Of Participants With At Least A 50% Reduction From Baseline To Month 6 In The Average Number Of Kidney Interstitial Capillary (IC) Globotriaosylceramide (GL-3) Inclusions (Baseline, Month 6): Migalastat — Responder: 13 Participants; Non-Responder: 19 Participants | Placebo — Responder: 9 Participants; Non-Responder: 23 Participants (missed)

Result source: NCT00925301

pegunigalsidase alfa

Marketed by Chiesi Farmaceutici and partners

Approved in Fabry Diseaseenzyme replacement
Weak signal

NCT03566017 · Phase 3 · completed

This was a genuine open-label extension of studies PB-102-F03, PB-102-F20, and PB-102-F30, with 97 participants and 81 completing the extension, but it was single-arm and unblinded with no comparator. Its primary focus was treatment-related adverse events rather than a randomized clinical efficacy comparison, so the findings provide useful long-term safety and descriptive follow-up evidence but cannot establish comparative treatment benefit. Its registered primary outcome on ClinicalTrials.gov is "Number of Participants With Treatment-related Adverse Events". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

Next expected readout: October 2027 · NCT05710692 (registry estimate)

Reported efficacy

Annualized Change (Slope) in Estimated Glomerular Filtration Rate (eGFR) (24 months): Annualized Change (Slope) in Estimated Glomerular Filtration Rate (eGFR) (24 months): PRX-102 (Pegunigalsidase Alfa) -2.514 mL/min/1.73 m^2/year (95% CI -3.788 to -1.24) | Agalsidase Beta -2.155 mL/min/1.73 m^2/year (95% CI -3.805 to -0.505) (met)

Result source: NCT02795676

Results for Fabry Disease

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Migalastat
Percentage Of Participants With At Least A 50% Reduction From Baseline To Month 6 In The Average Number Of Kidney Interstitial Capillary (IC) Globotriaosylceramide (GL-3) Inclusions (Baseline, Month 6): Migalastat — Responder: 13 Participants; Non-Responder: 19 Participants | Placebo — Responder: 9 Participants; Non-Responder: 23 Participants NCT00925301 · Phase 3 · design grade: moderate · reviewed ClinicalTrials.gov result
pegunigalsidase alfa
Annualized Change (Slope) in Estimated Glomerular Filtration Rate (eGFR) (24 months): PRX-102 (Pegunigalsidase Alfa) -2.514 mL/min/1.73 m^2/year (95% CI -3.788 to -1.24) | Agalsidase Beta -2.155 mL/min/1.73 m^2/year (95% CI -3.805 to -0.505) NCT02795676 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Migalastat's landscape · pegunigalsidase alfa's landscape